A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 3- Period, Crossover Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Two Dose Levels Of PF-04937319 In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2016
At a glance
- Drugs PF 4937319 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 02 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.